Impact of COVID 19 on red flag discussions for haematological malignancies within the Belfast trust.


Journal

The Ulster medical journal
ISSN: 2046-4207
Titre abrégé: Ulster Med J
Pays: Northern Ireland
ID NLM: 0417367

Informations de publication

Date de publication:
May 2021
Historique:
accepted: 29 03 2021
entrez: 19 7 2021
pubmed: 20 7 2021
medline: 23 7 2021
Statut: ppublish

Résumé

During the COVID-19 pandemic, there have been suggestions that there will be a reduction in cancer diagnoses, causing a detrimental effect on patients1. We therefore conducted an analysis to assess if there has been a reduction in new haematological malignancy diagnoses within the Belfast Health and Social Care Trust (BHSCT). We observed a significant decline in diagnostic tests used in the diagnosis of haematological malignancies. We therefore decided to analyse the impact of COVID-19 on the volume of tests performed to see if this impacted the number of new cases of haematological malignancies diagnosed. To ascertain the number of new diagnoses referred to Clinical Haematology we decided to analyse the number of new diagnoses discussed at the local Multidisciplinary Team Meetings (MDM) between March and June 2020 and compare this with the same period in 2019. In line with NICE guidelines2 there has been no change to the referral pathway for patients with new haematological malignancy. Results show that there is no significant difference between the number of new malignant haematological diagnoses discussed during March to June 2020 and the same period in 2019. This confirms that the number of new diagnoses remains the same within the two time periods. This analysis highlights that despite a reduction in primary and secondary care diagnostic blood tests, there is no difference in the number of new cases of haematological malignancies discussed at Haematology MDM throughout the first surge of the COVID-19 pandemic locally.

Identifiants

pubmed: 34276084
pmc: PMC8278935

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

77-80

Informations de copyright

Copyright © 2021 Ulster Medical Society.

Déclaration de conflit d'intérêts

Conflict of Interest: No conflicts of interest to declare.

Références

Ir J Med Sci. 2021 Feb;190(1):27-28
pubmed: 32638153
Lancet Oncol. 2020 Aug;21(8):1035-1044
pubmed: 32702311
Br J Haematol. 2011 Jul;154(1):32-75
pubmed: 21569004
Mayo Clin Proc. 2010 Oct;85(10):933-42
pubmed: 20713974
BMJ Open. 2019 Sep 17;9(9):e028362
pubmed: 31530591
Br J Haematol. 2015 Jan;168(2):207-18
pubmed: 25312307

Auteurs

David Waddell (D)

Haematology SpR, Department of Haematology, Belfast City Hospital (UK).

Gary Benson (G)

Consultant Haematologist, Department of Haematology, Belfast City Hospital (UK).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH